Orion Peptides
Popular

,

Tirz (G.L.P) 40mg

| Third-Party Tested | 99% Purity | COA Available | Research Use Only

Tirz (G.L.P) is a synthetic peptide that belongs to a new class of metabolic research compounds known as dual G.I.P and G.L.P-1 receptor agonists.

$197.00

5 out of 5 · 1 rating
Rate this compound:

Bulk Pricing – Save More

3
Buy 3 units 5% OFF
$187.15 each Total: $561.45 (Save $29.55)
5
Buy 5 units 10% OFF
$177.30 each Total: $886.50 (Save $98.50)
10
Buy 10 units 15% OFF
$167.45 each Total: $1674.50 (Save $295.50)
Clear selection
  • ≥99% (HPLC)
  • Third-Party Tested
  • Fast Shipping
  • Research Grade

Buy Tirz (G.L.P) 40mg

Tirz (G.L.P) is a synthetic peptide that belongs to a new class of metabolic research compounds known as dual G.I.P and G.L.P-1 receptor agonists. It is the first single molecule designed to activate both the glucose-dependent insulinotropic polypeptide (G.I.P) receptor and the glucagon-like peptide-1 (G.L.P-1) receptor at the same time. This dual mechanism makes Tirz (G.L.P) different from earlier G.L.P-1 receptor agonists, which target only one receptor.

Research background: Tirzepatide research profile · Retatrutide vs Tirzepatide vs Semaglutide

Researchers developed Tirz (G.L.P) to improve glucose regulation while also supporting body weight reduction. It is a 39-amino acid peptide with a fatty acid side chain that binds to albumin in the bloodstream. This modification extends its half-life to about 5 days, allowing for once-weekly administration in clinical studies.

Brief History of Tirz (G.L.P)

The development of Tirz (G.L.P) began at the developer under the research name LY3298176. Scientists designed the molecule by combining the biological actions of G.I.P and G.L.P-1 into a single peptide. Their goal was to create a therapy with greater metabolic benefits than existing G.L.P-1 receptor agonists. The first preclinical studies showed encouraging improvements in blood glucose control and body weight. These results led to a series of large human clinical trials, including the SURPASS program for type 2 diabetes and the SURMOUNT program for obesity. These studies consistently demonstrated strong improvements in blood glucose levels and significant reductions in body weight compared with placebo and several existing treatments. In May 2022, the U.S. Food and Drug Administration (FDA) approved Tirz (G.L.P) under the brand name brand-name tirzepatide for improving blood glucose control in adults with type 2 diabetes. In November 2023, the FDA also approved it under the brand name brand-name tirzepatide for chronic weight management in adults with obesity or overweight and at least one weight-related condition.

Research and Clinical Evidence

Tirz (G.L.P) has become one of the most extensively studied metabolic peptides in recent years. Clinical research has included thousands of participants across multiple countries. Key findings from major studies include:
  • The SURPASS clinical trials showed that Tirz (G.L.P) significantly reduced HbA1c levels compared with insulin and several G.L.P-1 receptor agonists.
  • In the SURMOUNT-1 trial, participants without diabetes achieved an average body weight reduction of up to about 22.5% after 72 weeks at the highest dose, one of the largest reductions reported for a medication in obesity research.
  • FDA approval for diabetes was supported by nine clinical trials involving 7,769 participants, with more than 5,400 receiving Tirz (G.L.P).
  • Research suggests that the combined activation of G.I.P and G.L.P-1 receptors improves insulin secretion, reduces glucagon release, delays gastric emptying, and decreases food intake more effectively than G.L.P-1 receptor activation alone.

Why Tirz (G.L.P) Is Important

Tirz (G.L.P) introduced a new approach to metabolic research by targeting two important incretin pathways with a single peptide. Its success has encouraged researchers to investigate dual- and multi-receptor agonists for obesity, diabetes, cardiovascular disease, kidney disease, and other metabolic disorders. Today, Tirz (G.L.P) serves as an important reference molecule in incretin-based therapeutic research.

Selected Research Papers

  1. Coskun T, et al. (2018). LY3298176, a novel dual G.I.P and G.L.P-1 receptor agonist for the treatment of type 2 diabetes. Journal of Medicinal Chemistry.
  2. Jastreboff AM, et al. (2022). Tirz (G.L.P) Once Weekly for the Treatment of Obesity. New England Journal of Medicine.
  3. Frías JP, et al. (2021). Tirz (G.L.P) versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine.
  4. Del Prato S, et al. (2021). Tirz (G.L.P) versus Insulin Glargine in Type 2 Diabetes (SURPASS-3). The Lancet.
  5. Min T, Bain SC. (2023). Tirz (G.L.P), a New Class of Incretin-Based Drug for Diabetes. Exploration of Medicine.
 

Research Use Only

This compound is intended for laboratory research use only. It is not intended for human or animal consumption, or for use in diagnostic or therapeutic procedures.

Certificate of Analysis

Quality

Every batch of Tirz (G.L.P) 40mg is tested for purity and identity using industry-standard methods.

HPLC Analysis

High-Performance Liquid Chromatography confirms purity ≥99%. Each batch is analyzed to ensure consistent quality.

Mass Spectrometry (MS)

Identity verification via mass spectrometry confirms correct molecular weight of 4113.58 g/mol.

Third-Party Testing

All compounds undergo independent third-party laboratory testing for quality assurance.

Request COA

Certificate of Analysis documents are available for all compounds. Contact us with your order number to request batch-specific documentation.

Contact Support

COA Lab Tests

Each compound batch is tested by independent laboratories to verify purity, identity, and quality. The Certificate of Analysis (COA) provides transparent lab results, ensuring the compound meets strict research-grade standards.

⁠Current Batch Test Results
Past Batches Test Results
Search By your Order Number or Batch Number

Storage & Handling

Related Compounds

Lipo-C + B12 10ml

Buy Lipo-C + B12 10mg

$20.00

Add
buy B12 10mg

Buy B12 10mg

$9.00

Add
Buy PE-22-28 10mg

Buy PE-22-28 10mg

$69.00

Add
Buy CJC-1295 No DAC 10mg

Buy CJC-1295 (No DAC) 10mg

$64.00

Add
SS-31 Peptide 10mg Buy Online

Buy SS-31 (Elamipretide) 10mg

$68.00

Add
Buy RT-10mg

Buy RT – 10mg

$81.00

Add
Buy KPV 10mg

KPV 10mg

$49.00

Add
Buy MOTS-C 40mg

MOTS-C 40mg

$110.00

Add
Buy Glutathione - 1500mg

Glutathione 1500mg

$82.00

Add
Buy Acetic Acid 10 ml

Acetic Acid 10ml

$14.00

Add
Buy GHRP-6 5mg

GHRP-6 5mg

$17.00

Add
Buy Tesamorelin + Ipamorelin Blend for sale 10mg

Tesamorelin + Ipamorelin – 10MG (Blend)

$170.00

Add
×
On Sale
Out of Stock

Storage

Store at -20°C.
Protect from light and moisture.

View Full Details
Added to cart successfully!

Certificate of Analysis

ORP#00023
Client:
Orion Peptides
Sample:
GLP-2-TR 40mg
Batch:
202601TR40
Tests Requested:
Standard + Endotoxins + Sterility
Appearance:
White Lyophilized Powder in 3mL Vial
Analysis Conducted on:
01/11/2026
Report Issued on:
08/01/2026
Test Method Result Specification  
Identity HPLC-DAD Tirzepatide GLP-2-TR Pass
Purity HPLC-DAD 99.77 >99% by HPLC Pass
Quantity HPLC Analyte Concentration Curve Assay 45.23mg 40mg Pass
Endotoxins LAL ELISA 0.195 EU/mL ≤ 0.5 EU/mL Pass
Sterility Pour Plate No Growth No Growth Pass
Disclaimer: The data contained in this report is representative of the received sample. This analysis is for informational purposes only. The tested substances are intended for research use only and are not approved for human or veterinary use, diagnostic, therapeutic, or clinical applications. All data was obtained under standard laboratory conditions.
QR Verification Code